Half a century of advancements in biomedical science paved the way for today's powerful weight-loss drugs like Ozempic—so ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...

One of the researchers described the circumstances that led to the discovery as “serendipity.” This year’s prestigious Lasker ...

It’s a brain disease,” a prominent obesity doctor explained on a “60 Minutes” episode about the drugs. “Obesity is disease” ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

In the heavyweight title match between weight loss meds, we have ourselves a victor.In the battle between Novo Nordisk’s ...

Why Corbus Pharmaceuticals sees Novo Nordisk’s controversial approach to obesity drugs as a ticket to a blockbuster.

The Northeast Microelectronics Coalition Hub announced on Wednesday that it had been awarded $37.8 million in federal ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.